Revenue Breakdown
Composition ()
No data
Revenue Streams
Indivior Pharmaceuticals, Inc (INDV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SUBLOCADE, accounting for 64.2% of total sales, equivalent to $192.00M. Other significant revenue streams include Sublingual/Other and PERSERIS. Understanding this composition is critical for investors evaluating how INDV navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Indivior Pharmaceuticals, Inc maintains a gross margin of 73.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.69%, while the net margin is 13.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively INDV converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, INDV competes directly with industry leaders such as ACAD and ERAS. With a market capitalization of $3.86B, it holds a significant position in the sector. When comparing efficiency, INDV's gross margin of 73.57% stands against ACAD's 90.77% and ERAS's N/A. Such benchmarking helps identify whether Indivior Pharmaceuticals, Inc is trading at a premium or discount relative to its financial performance.
